Drugs / epigallocatechin-3-gallate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02580279 | Dec 2014 → Aug 2019 | breast neoplasm, dermatitis | Shandong Cancer Hospital and Institute | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epigallocatechin-3-gallate | “To evaluate the safety and effectiveness of epigallocatechin-3-gallate (EGCG) solution treating the acute severe dermatitis in patients receiving radiotherapy.” PMID 37620508 ↗ Aug 2023 |
| Known as | EGCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02580279 ↗ |
| Route | Topical | “EGCG solution (660 μmol/L) or placebo (0.9% NaCl saline) sprayed to the whole radiation field from day 1 of the radiation until 2 weeks after radiation completion.” PMID 35648426 ↗ Jul 2022 |